{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T13:35:55Z","timestamp":1793885755251,"version":"4.8.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.jtct.2026.06.023","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T16:04:32Z","timestamp":1781798672000},"page":"1497.e1-1497.e15","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical Trials in Graft-Versus-Host Disease: Changes in Study Characteristics, Investigated Drugs, and Endpoints Over Time"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8920-0206","authenticated-orcid":false,"given":"Philipp","family":"Melhorn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Dominik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina Zoe","family":"R\u00fcsing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Cserna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna A.","family":"Knaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Schulenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margit","family":"Mitterbauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hildegard T.","family":"Greinix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Werner","family":"Rabitsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2026.06.023_bib0001","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1146\/annurev-immunol-102119-073227","article-title":"Current Concepts and Advances in Graft-Versus-Host Disease Immunology","volume":"39","author":"Hill","year":"2021","journal-title":"Annu Rev Immunol"},{"issue":"9674","key":"10.1016\/j.jtct.2026.06.023_bib0002","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1016\/S0140-6736(09)60237-3","article-title":"Graft-versus-host disease","volume":"373","author":"Ferrara","year":"2009","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.jtct.2026.06.023_bib0003","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.bbmt.2016.09.023","article-title":"The Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease","volume":"23","author":"Cooke","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.jtct.2026.06.023_bib0004","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.jtct.2026.06.023_bib0005","doi-asserted-by":"crossref","first-page":"2","DOI":"10.5045\/br.2023.2022192","article-title":"Effects of immune system cells in GvHD and corresponding therapeutic strategies","volume":"58","author":"Tavaf","year":"2023","journal-title":"Blood Res"},{"issue":"2","key":"10.1016\/j.jtct.2026.06.023_bib0006","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/S2352-3026(23)00342-3","article-title":"Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation","volume":"11","author":"Penack","year":"2024","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtct.2026.06.023_bib0007","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/ajh.27592","article-title":"Steroid Refractory Acute GVHD: The Hope for a Better Tomorrow","volume":"100 Suppl 3","author":"Smallbone","year":"2025","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtct.2026.06.023_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.coi.2025.102654","article-title":"Approved and emerging therapies for glucocorticoid-refractory chronic graft-versus-host disease","volume":"97","author":"Zhang","year":"2025","journal-title":"Curr Opin Immunol"},{"issue":"19","key":"10.1016\/j.jtct.2026.06.023_bib0009","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa1917635","article-title":"Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease","volume":"382","author":"Zeiser","year":"2020","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jtct.2026.06.023_bib0010","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2033122","article-title":"Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease","volume":"385","author":"Zeiser","year":"2021","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.jtct.2026.06.023_bib0011","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1182\/blood.2024026633","article-title":"FDA-approved therapies for chronic GVHD","volume":"145","author":"Lee","year":"2025","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.jtct.2026.06.023_bib0012","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1182\/blood.2021012021","article-title":"Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar study","volume":"138","author":"Cutler","year":"2021","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.jtct.2026.06.023_bib0013","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2401537","article-title":"Axatilimab in Recurrent or Refractory Chronic Graft-versus-Host Disease","volume":"391","author":"Wolff","year":"2024","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.jtct.2026.06.023_bib0014","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1182\/blood-2017-07-793786","article-title":"Ibrutinib for chronic graft-versus-host disease after failure of prior therapy","volume":"130","author":"Miklos","year":"2017","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jtct.2026.06.023_bib0015","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.bbmt.2020.01.018","article-title":"A Phase 3, Single-Arm, Prospective Study of Remestemcel-L, Ex Vivo Culture-Expanded Adult Human Mesenchymal Stromal Cells for the Treatment of Pediatric Patients Who Failed to Respond to Steroid Treatment for Acute Graft-versus-Host Disease","volume":"26","author":"Kurtzberg","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"10.1016\/j.jtct.2026.06.023_bib0016","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1016\/j.bbmt.2015.05.004","article-title":"National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. The 2014 Clinical Trial Design Working Group Report","volume":"21","author":"Martin","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"10.1016\/j.jtct.2026.06.023_bib0017","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.jtct.2021.05.004","article-title":"National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2020 Treatment of Chronic GVHD Report","volume":"27","author":"DeFilipp","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2026.06.023_bib0018","unstructured":"ClinicalTrials.gov. About ClinicalTrials.Gov; 2024. https:\/\/clinicaltrials.gov\/about-site\/about-ctg. Accessed January 10, 2026"},{"issue":"1","key":"10.1016\/j.jtct.2026.06.023_bib0019","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1186\/s13063-022-06569-2","article-title":"Update on the clinical trial landscape: analysis of ClinicalTrials.Gov registration data, 2000-2020","volume":"23","author":"Gresham","year":"2022","journal-title":"Trials"},{"key":"10.1016\/j.jtct.2026.06.023_bib0020","unstructured":"ClinicalTrials.gov. Protocol Registration Data Element Definitions for Interventional and Observational Studies; 2025. https:\/\/clinicaltrials.gov\/policy\/protocol-defnitions. Accessed January 10, 2026"},{"issue":"16","key":"10.1016\/j.jtct.2026.06.023_bib0021","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1001\/jama.2023.2351","article-title":"Comparison of Availability of Trial Results in ClinicalTrials.gov and PubMed by Data Source and Funder Type","volume":"329","author":"Nelson","year":"2023","journal-title":"Jama"},{"issue":"11","key":"10.1016\/j.jtct.2026.06.023_bib0022","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJMsa1409364","article-title":"Compliance with results reporting at ClinicalTrials.Gov","volume":"372","author":"Anderson","year":"2015","journal-title":"N Engl J Med"},{"issue":"43","key":"10.1016\/j.jtct.2026.06.023_bib0023","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.21105\/joss.01686","article-title":"Welcome to the Tidyverse","volume":"4","author":"Wickham","year":"2019","journal-title":"J Open Source Softw"},{"key":"10.1016\/j.jtct.2026.06.023_bib0024","unstructured":"Wickham H. httr: Tools for Working with URLs and HTTP. R package version 1.4.7; 2023. https:\/\/CRAN.R-project.org\/package=httr. Accessed December 31, 2024"},{"issue":"1","key":"10.1016\/j.jtct.2026.06.023_bib0025","doi-asserted-by":"crossref","first-page":"570","DOI":"10.32614\/RJ-2021-053","article-title":"Reproducible summary tables with the gtsummary package","volume":"13","author":"Sjoberg","year":"2021","journal-title":"The R J"},{"key":"10.1016\/j.jtct.2026.06.023_bib0026","unstructured":"Massicotte P, South A. rnaturalearth: World Map Data from Natural Earth. R package version 1.0.1; 2023.https:\/\/CRAN.R-project.org\/package=rnaturalearth. Accessed December 31, 2024"},{"key":"10.1016\/j.jtct.2026.06.023_bib0027","author":"Mike"},{"key":"10.1016\/j.jtct.2026.06.023_bib0028","author":"Ooms"},{"key":"10.1016\/j.jtct.2026.06.023_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115673","article-title":"Availability and characteristics of clinical trials for neuroendocrine tumors: Is there an unmet need?","volume":"227","author":"Melhorn","year":"2025","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.jtct.2026.06.023_bib0030","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S0895-4356(00)00314-0","article-title":"Adjusting for multiple testing\u2013when and how?","volume":"54","author":"Bender","year":"2001","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"10.1016\/j.jtct.2026.06.023_bib0031","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1056\/NEJMsr1601330","article-title":"Update on Trial Registration 11 Years after the ICMJE Policy Was Established","volume":"376","author":"Zarin","year":"2017","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.jtct.2026.06.023_bib0032","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1056\/NEJM197905103001902","article-title":"Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts","volume":"300","author":"Weiden","year":"1979","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jtct.2026.06.023_bib0033","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1182\/blood.V75.3.555.555","article-title":"Graft-versus-leukemia reactions after bone marrow transplantation","volume":"75","author":"Horowitz","year":"1990","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.jtct.2026.06.023_bib0034","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1182\/blood.2025028617","article-title":"Challenges in GVHD and GVL after hematopoietic stem cell transplantation for myeloid malignancies","volume":"146","author":"Socie","year":"2025","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jtct.2026.06.023_bib0035","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1182\/blood-2017-03-775767","article-title":"An endpoint associated with clinical benefit after initial treatment of chronic graft-versus-host disease","volume":"130","author":"Martin","year":"2017","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jtct.2026.06.023_bib0036","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.3324\/haematol.2020.265769","article-title":"Improved outcome of patients with graft-versus-host disease after allogeneic hematopoietic cell transplantation for hematologic malignancies over time: an EBMT mega-file study","volume":"107","author":"Greinix","year":"2022","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.jtct.2026.06.023_bib0037","doi-asserted-by":"crossref","first-page":"36","DOI":"10.2991\/chi.d.190314.001","article-title":"Challenges in Conducting Studies in Chronic Graft-versus-Host Disease","volume":"1","author":"Pusic","year":"2019","journal-title":"Clin Hematol Int"},{"issue":"11","key":"10.1016\/j.jtct.2026.06.023_bib0038","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1038\/s41409-018-0204-7","article-title":"EBMT-NIH-CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment","volume":"53","author":"Schoemans","year":"2018","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"10.1016\/j.jtct.2026.06.023_bib0039","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2025.05.016","article-title":"NIH Chronic Graft-Versus-Host Disease Consensus Conference 2025 Update","volume":"31","author":"Lee","year":"2025","journal-title":"Transplant Cell Ther"},{"issue":"22","key":"10.1016\/j.jtct.2026.06.023_bib0040","doi-asserted-by":"crossref","first-page":"5763","DOI":"10.1182\/bloodadvances.2025017116","article-title":"The MAGIC composite response: a novel end point integrating clinical and biomarker parameters for acute GVHD","volume":"9","author":"Akahoshi","year":"2025","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.jtct.2026.06.023_bib0041","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1001\/jamadermatol.2023.6276","article-title":"Improving Outcomes in Chronic Graft-vs-Host Disease","volume":"160","author":"Mitchell","year":"2024","journal-title":"JAMA Dermatol"},{"issue":"6","key":"10.1016\/j.jtct.2026.06.023_bib0042","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.bbmt.2015.02.025","article-title":"Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group report","volume":"21","author":"Lee","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"17","key":"10.1016\/j.jtct.2026.06.023_bib0043","doi-asserted-by":"crossref","first-page":"4651","DOI":"10.1182\/blood-2010-11-319509","article-title":"Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium","volume":"117","author":"Pidala","year":"2011","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jtct.2026.06.023_bib0044","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s11899-019-0494-x","article-title":"Graft Versus Host Disease Clinical Trials: Is it Time for Patients Centered Outcomes to Be the Primary Objective?","volume":"14","author":"Shaw","year":"2019","journal-title":"Curr Hematol Malig Rep"},{"issue":"27","key":"10.1016\/j.jtct.2026.06.023_bib0045","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000029634","article-title":"A bibliometric analysis of global publications on graft-versus-host disease research","volume":"101","author":"Huang","year":"2022","journal-title":"Medicine (Baltimore)"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726004914?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726004914?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T13:19:42Z","timestamp":1793884782000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636726004914"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":45,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S2666636726004914"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2026.06.023","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Trials in Graft-Versus-Host Disease: Changes in Study Characteristics, Investigated Drugs, and Endpoints Over Time","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2026.06.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of American Society for Transplantation and Cellular Therapy.","name":"copyright","label":"Copyright"}]}}